# Bioavailability of BIBR 953 ZW After BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as Hydroxypropyl Methylcellulose (HPMC) Polymorph II Capsule Relative to HPMC Polymorph I Capsule in Healthy Subjects.

> **NCT02170974** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 28 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIBR 1048 MS polymorph II
- **DRUG:** BIBR 1048 MS polymorph I

## Key facts

- **NCT ID:** NCT02170974
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2004-08
- **Final completion:** —
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2014-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02170974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02170974, "Bioavailability of BIBR 953 ZW After BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as Hydroxypropyl Methylcellulose (HPMC) Polymorph II Capsule Relative to HPMC Polymorph I Capsule in Healthy Subjects.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02170974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*